> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lenz Plans NDA for Presbyopia Eye Drops
- URL: https://www.fdaweb.com/lenz-plans-nda-for-presbyopia-eye-drops/
- Published: 2024-04-03T12:00:00.000Z
- Updated: 2026-09-14T14:27:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156702

Lenz Therapeutics says it will file an NDA for aceclidine eye drops in a few months after reporting Phase 3 study results for treating presbyopia, which affects near vision in people over 45\. The data from CLARITY 1 and 2 trials showed that LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity near vision test without losing one-line or more in distance visual acuity. In the vehicle-controlled CLARITY 2 trial, data showed a rapid onset (71% achieved three-lines or greater improvement at 30 minutes), and a long duration (40% achieved three-lines or greater improvement at 10 hours), according to the company.

Lenz says the drug was well-tolerated with no serious treatment-related adverse events observed in the over 30,000 treatment days across all CLARITY trials.